Influenza B virus with modified hemagglutinin cleavage site as a novel attenuated live vaccine

Journal of Infectious Diseases

Volumn 204, Issue 10, 2011, Pages 1483-1490

  Stech, Jürgen ^a   Garn, Holger ^b   Herwig, Astrid ^c   Stech, Olga ^a   Dauber, Bianca ^d,e   Wolff, Thorsten ^d   Mettenleiter, Thomas C ^a   Klenk, Hans Dieter ^c  

^a FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^b Biomedizinisches Forschungszentrum   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d ROBERT KOCH INSTITUTE   (Germany)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LIVE VACCINE; NEUTRALIZING ANTIBODY; PANCREATIC ELASTASE; PROTEINASE; TRYPSIN; VALINE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; EXPERIMENTAL INFECTION; FEMALE; GENETIC PROCEDURES; HEMAGGLUTININ CLEAVAGE SITE MUTANT INFLUENZA VIRUS B; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS B; LUNG INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN ENGINEERING; REVERSE GENETICS; SURVIVAL; VIRUS ACTIVATION; VIRUS ATTENUATION; VIRUS ISOLATION; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TITRATION; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION, VIRAL; INFLUENZA B VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MUTATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 80054768655     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir613     Document Type: Conference Paper

References (49)

1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86. (Pubitemid 36068705)
2. Berton MT, Webster RG. The antigenic structure of the influenza B virus hemagglutinin: operational and topological mapping with monoclonal antibodies. Virology 1985; 143:583-94. (Pubitemid 15035305)
3. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990; 175:59-68.
4. Nakagawa N, Kubota R, Morikawa S, Nakagawa T, Baba K, Okuno Y. Characterization of new epidemic strains of influenza B virus by using neutralizing monoclonal antibodies. J Med Virol 2001; 65:745-50. (Pubitemid 33135104)
5. Nakagawa N, Nukuzuma S, Haratome S, Go S, Nakagawa T, Hayashi K. Emergence of an influenza B virus with antigenic change. J Clin Microbiol 2002; 40:3068-70. (Pubitemid 35284993)
6. Wang Q, Cheng F, Lu M, Tian X, Ma J. Crystal structure of unliganded influenza B virus hemagglutinin. J Virol 2008; 82:3011-20. (Pubitemid 351329189)
7. Shen J, Kirk BD, Ma J, Wang Q. Diversifying selective pressure on influenza B virus hemagglutinin. J Med Virol 2009; 81:114-24.
8. Wang Q. Influenza type B virus haemagglutinin: antigenicity, receptor binding and membrane fusion. In: Wang Q, Tao YJ ed. Influenza. Molecular biology. Norfolk, United Kingdom: Caister Academic Press, 2010:29-52.
9. McCullers JA, Wang GC, He S, Webster RG. Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature. J Virol 1999; 73:7343-8. (Pubitemid 29383217)
10. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28(Suppl 4):D45-53.
11. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010; 28:2149-56.
12. Yang CF, Belshe RB, Kemble G, et al. Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine. Vaccine 2010; 28:5128-34.
13. Maassab HF, DeBorde DC. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 1985; 3: 355-69. (Pubitemid 16201989)
14. Maassab HF, Bryant ML. The development of live attenuated coldadapted influenza virus vaccine for humans. Rev Med Virol 1999; 9:237-44.
15. Chen Z, Aspelund A, Kemble G, Jin H.Molecular studies of temperaturesensitive replication of the cold-adapted B/Ann Arbor/1/66, the master donor virus for live attenuated influenza FluMist vaccines. Virology 2008; 380:354-62.
16. Talon J, Salvatore M, O'Neill RE, et al. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc Natl Acad Sci U S A 2000; 97:4309-14. (Pubitemid 30226129)
17. Wressnigg N, Voss D, Wolff T, et al. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate. Vaccine 2009; 27:2851-7.
18. Stech J, Garn H, Wegmann M, Wagner R, Klenk HD. A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nat Med 2005; 11:683-9. (Pubitemid 40868311)
19. Gabriel G, Garn H, Wegmann M, et al. The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine. Vaccine 2008; 26:956-65.
20. Klenk HD, Rott R, Orlich M, Blodorn J. Activation of influenza A viruses by trypsin treatment. Virology 1975; 68:426-39.
21. Lazarowitz SG, Choppin PW. Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 1975; 68:440-54.
22. Huang RTC, Wahn K, Klenk HD, Rott R. Fusion between cell membranes and liposomes containing the glycoprotein of influenza virus. Virology 1980; 104:294-302. (Pubitemid 10085907)
23. Maeda T, Ohnishi S. Activation of influenza virus by acidic media causes hemolysis and fusion of erythrocytes. FEBS Lett 1980; 122:283-7. (Pubitemid 11186279)
24. White JM, Matlin K, Helenius A. Cell fusion by Semliki Forest, influenza, and vesicular stomatitis viruses. J Cell Biol 1981; 89:674-9. (Pubitemid 11035975)
25. Bullough P, Hughson FM, Skehel JJ, Wiley DC. The structure of influenza hemagglutinin at the pH of membrane fusion. Nature 1994; 371:37-43. (Pubitemid 24277462)
26. Masic A, Booth JS, Mutwiri GK, Babiuk LA, Zhou Y. Elastasedependent live attenuated swine influenza A viruses are immunogenic and confer protection against swine influenza A virus infection in pigs. J Virol 2009; 83:10198-210.
27. Masic A, Lu X, Li J, et al. Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine influenza virus vaccine administered intranasally in pigs. Vaccine 2010; 28:7098-108.
28. Babiuk S, Masic A, Graham J, et al. An elastase-dependent attenuated heterologous swine influenza virus protects against pandemic H1N1 2009 influenza challenge in swine. Vaccine 2011; 29:3118-23.
29. Garten W, Klenk HD. Cleavage activation of the influenza virus hemagglutinin and its role in pathogenesis. In: Klenk HD, Matrosovich MN, Stech J ed. Avian influenza. Vol 27. Basel, Switzerland: Karger, 2008:156-67.
30. Brassard DL, Lamb RA. Expression of influenza B virus hemagglutinin containing multibasic residue cleavage sites. Virology 1997; 236:234-48. (Pubitemid 27423766)
31. Dauber B, Heins G, Wolff T. The influenza B virus nonstructural NS1 protein is essential for efficient viral growth and antagonizes beta interferon induction. J Virol 2004; 78:1865-72. (Pubitemid 38176718)
32. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 2000; 97:6108-13. (Pubitemid 30367531)
33. Stech J, Xiong X, Scholtissek C, Webster RG. Independence of evolutionary and mutational rates after transmission of avian influenza viruses to swine. J Virol 1999; 73:1878-84. (Pubitemid 29098088)
34. Mecham RP, Broekelmann TJ, Fliszar CJ, Shapiro SD, Welgus HG, Senior RM. Elastin degradation by matrix metalloproteinases: cleavage site specificity and mechanisms of elastolysis. J Biol Chem 1997; 272: 18071-6. (Pubitemid 27306388)
35. Couch RB. Seasonal inactivated influenza virus vaccines. Vaccine 2008; 26(Suppl 4):D5-9.
36. Barr IG, McCauley J, Cox N, et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 Northern Hemisphere season. Vaccine 2009; 28:1156-67.
37. Gauger PC, Vincent AL, Loving CL, et al. Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (delta-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine 2011; 29:2712-9.
38. Vincent AL, Lager KM, Janke BH, Gramer MR, Richt JA. Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. Vet Microbiol 2008; 126:310-23. (Pubitemid 350199605)
39. Bodewes R, Kreijtz JH, Rimmelzwaan GF. Yearly influenza vaccinations: A double-edged sword? Lancet Infect Dis 2009; 9:784-8.
40. Bodewes R, Kreijtz JH, Hillaire ML, et al. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. J Gen Virol 2010; 91:1743-53.
41. Bodewes R, Kreijtz JH, Geelhoed-Mieras MM, et al. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J Virol 2011; 85:2695-702.
42. Masic A, Babiuk LA, Zhou Y. Reverse genetics-generated elastasedependent swine influenza viruses are attenuated in pigs. J Gen Virol 2009; 90:375-85.
43. Nobusawa E, Sato K. Comparison of the mutation rates of human influenza A and B viruses. J Virol 2006; 80:3675-8.
44. McElhaney JE. Influenza vaccine responses in older adults. Ageing Res Rev 2010; 10:379-88.
45. Zhou X, McElhaney JE. Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans. Vaccine 2011; 29:2169-77.
46. Hai R,Martinez-Sobrido L, Fraser KA, Ayllon J, Garcia-Sastre A, Palese P. Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol 2008; 82:10580-90. (Pubitemid 352691164)
47. Seo SU, Byun YH, Lee EY, et al. Development and characterization of a live attenuated influenza B virus vaccine candidate. Vaccine 2008; 26:874-81.
48. van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, Oxford J. Animal models in influenza vaccine testing. Expert Rev Vaccines 2008; 7:783-93.
49. Palese P. Making better influenza virus vaccines? Emerg Infect Dis 2006; 12:61-5. (Pubitemid 43143537)